share_log

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB

bluebird bio | NT 10-Q:季報延遲披露公告
美股sec公告 ·  05/16 05:10
牛牛AI助理已提取核心訊息
bluebird bio, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. The delay is attributed to the ongoing restatement of the company's financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. Consequently, the company is unable to meet the May 15, 2024, filing deadline for the Quarterly Report. The restatement process has uncovered errors related to the accounting of embedded leases and the treatment of non-lease components in lease agreements with contract manufacturing organizations. Despite these issues, bluebird bio does not anticipate any impact on its cash position or revenue from these errors. The company has also indicated that there will be significant...Show More
bluebird bio, Inc. has announced a delay in filing its Quarterly Report on Form 10-Q for the first quarter ended March 31, 2024. The delay is attributed to the ongoing restatement of the company's financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. Consequently, the company is unable to meet the May 15, 2024, filing deadline for the Quarterly Report. The restatement process has uncovered errors related to the accounting of embedded leases and the treatment of non-lease components in lease agreements with contract manufacturing organizations. Despite these issues, bluebird bio does not anticipate any impact on its cash position or revenue from these errors. The company has also indicated that there will be significant changes in its results of operations for the quarter ended March 31, 2024, compared to the same period in 2023, but it is currently unable to provide an estimate of these changes. The notification filed with the SEC also includes forward-looking statements and acknowledges that the company's 2023 Form 10-K has not yet been filed.
藍鳥生物公司宣佈延遲提交截至2024年3月31日的第一季度10-Q表季度報告。延遲歸因於公司持續重報截至2022年12月31日的年度以及2022年和2023年前三個季度的財務報表。因此,該公司無法在2024年5月15日提交季度報告的截止日期之前提交。重報過程發現了與嵌入式租賃會計以及與合同製造組織簽訂的租賃協議中對非租賃部分的處理有關的錯誤。儘管存在這些問題,但bluebird bio預計這些錯誤不會對其現金狀況或收入產生任何影響。該公司還表示,與2023年同期相比,截至2024年3月31日的季度經營業績將發生重大變化,但目前無法提供這些變化的估計。向美國證券交易委員會提交的通知還包括前瞻性陳述,並承認該公司尚未提交2023年10-K表格。
藍鳥生物公司宣佈延遲提交截至2024年3月31日的第一季度10-Q表季度報告。延遲歸因於公司持續重報截至2022年12月31日的年度以及2022年和2023年前三個季度的財務報表。因此,該公司無法在2024年5月15日提交季度報告的截止日期之前提交。重報過程發現了與嵌入式租賃會計以及與合同製造組織簽訂的租賃協議中對非租賃部分的處理有關的錯誤。儘管存在這些問題,但bluebird bio預計這些錯誤不會對其現金狀況或收入產生任何影響。該公司還表示,與2023年同期相比,截至2024年3月31日的季度經營業績將發生重大變化,但目前無法提供這些變化的估計。向美國證券交易委員會提交的通知還包括前瞻性陳述,並承認該公司尚未提交2023年10-K表格。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。